查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012283

Castleman氏病治療市場：全球市場按治療方法、治療階段、分銷管道和最終用戶分類的預測，2026-2032年

Castleman Disease Treatment Market by Treatment Type, Line Of Therapy, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Castleman氏病治療市場價值將達到 3.8066 億美元，到 2026 年將成長至 4.3111 億美元，到 2032 年將達到 9.5452 億美元，年複合成長率為 14.03%。

主要市場統計數據
基準年 2025 3.8066億美元
預計年份：2026年 4.3111億美元
預測年份 2032 9.5452億美元
複合年成長率 (%) 14.03%

對Castleman氏病臨床複雜性以及決定治療策略的治療和護理服務體系的演變進行策略性概述。

Castleman氏病在臨床和治療方面都面臨著複雜的挑戰，涉及免疫學、腫瘤學和罕見疾病管理等多個領域。患者的臨床表現多種多樣，從可局部治療的單中心病例到需要持續多學科診療的多中心和系統性病例均有涉及。儘管診斷延遲和臨床表現的多樣性加劇了未滿足的醫療需求，但對細胞激素訊號傳導核心作用的深入理解正在重新定義臨床實踐中的治療重點。

重塑Castleman氏病治療的最重要變化來自於生物目標、生物標記主導的策略和新的護理服務模式。

機制和治療方法的最新進展正在推動整個研究、臨床實踐和患者支持模式的變革性轉變。對白細胞介素-6通路和細胞激素調節的日益關注，促使研究投資重新分配至生物製藥和單克隆抗體領域，與此同時，生物標記發現工作也在同步進行，旨在對患者進行分層，以便更精準地進行干預，並識別最有可能持續獲益的患者。這項科學轉變正在引發一系列連鎖反應，影響試驗設計、對照組選擇和監管對話。

2025 年美國關稅政策變更對供應鏈、籌資策略以及持續獲得Castleman氏病治療的影響。

美國於2025年實施的關稅調整為參與罕見免疫介導疾病治療的製造商、經銷商和醫療服務提供者帶來了新的考量。即使主要生物製藥本身是在特殊的貿易條件下生產的，活性成分、一次性醫療器材、包裝材料和低溫運輸物流等輔助投入品也容易受到跨境成本波動的影響。隨著進口關稅和物流附加費的波動，相關人員需要重新評估其採購政策和庫存策略，以確保弱勢患者群體獲得持續的醫療服務。

詳細的細分洞察，解釋了治療類型、治療線、分銷管道和醫療保健服務環境如何影響臨床和商業性績效。

清晰了解患者的人口統計學特徵和治療路徑對於解讀治療反應和製定商業性策略至關重要。治療細分區分了化療和生物目標製劑，進一步分析了化療模式（聯合治療和單藥治療），並按具體藥物（如地塞米松和潑尼松）對皮質類固醇的使用進行了分類。這種詳細的分析闡明了臨床實踐中哪些情況下更傾向於使用廣譜免疫抑製而非精準標靶治療，有助於對安全性和耐受性進行比較評估，而這對於臨床醫生的決策至關重要。

美洲、歐洲、中東和非洲以及亞太地區的區域差異如何決定准入路線、部署模式和商業性方法。

區域趨勢對臨床應用、報銷策略和取得途徑有顯著影響。在美洲，專科中心和成熟的轉診網路加速了標靶生技藥品的引入，並支持積極的臨床試驗。同時，支付方框架和病患支援計畫影響著病患的自付費用及其在處方藥清單中的位置。儘管區域生態系統往往有利於實證醫學證據快速應用於臨床實踐，但由於醫療服務環境和患者群體的不同，獲取途徑仍有差異。

公司採取的商業和發展策略，旨在實現治療方法差異化、擴大覆蓋範圍並建立永續的證據生成項目。

在Castleman氏病領域，關鍵的商業和開發策略強調貫穿整個價值鏈的創新，而非單一差異化優勢。各公司優先考慮透過標靶作用機制實現持續的臨床獲益，並透過研究者主導的臨床試驗和註冊試驗拓展適應症範圍，同時兼顧生命週期管理和產品組合多元化，以降低單一產品風險。與生產商、臨床研究機構和專科藥房建立策略合作夥伴關係已成為擴大複雜生物製藥生產規模和簡化患者用藥途徑的常用策略。

為行業領導者提供切實可行的、高優先級的建議，以協調臨床創新、准入策略和業務永續營運，從而實現長期成功。

產業領導者應優先考慮一套整合且切實可行的措施，以協調臨床療效、可近性和業務永續營運。首先，提高診斷準確性並投資生物標記計畫將有助於更精準地篩選患者，並加強與保險公司的溝通，從而降低療效比較的不確定性。其次，實現生產和供應夥伴關係關係的多元化，包括區域生產能力和檢驗的替代供應商，將有助於降低關稅造成的成本轉移和物流中斷風險。

為了確保研究結果的可靠性，我們採用了嚴格的混合方法研究途徑，結合了臨床文獻、相關人員訪談和真實世界資料的檢驗。

本文的研究結果是基於混合方法研究，旨在平衡臨床嚴謹性和實際應用性。此調查方法整合了對同儕審查文獻和臨床試驗註冊庫的全面回顧，以及對治療醫師、專科藥劑師和保險公司代表的定性訪談，以了解治療模式和報銷決定因素。此外，還分析了來自真實世界資料來源和觀察性研究註冊庫的證據，以檢驗治療路徑，並在非對照試驗環境下分析藥物依從性和安全性。

將Castleman氏病治療創新轉化為永續的臨床和營運影響：證據與策略方向的簡潔整合。

總之，生物目標療法的進步和不斷發展的醫療服務模式正在重塑Castleman氏病的治療格局，這不僅為相關人員帶來了機遇，也帶來了責任。儘管細胞激素調控的科學進步已為許多患者帶來了顯著的改善，但與藥物可近性、供應鏈韌性和醫保報銷環境波動相關的結構性挑戰依然存在。應對這些挑戰需要臨床、商業和營運部門通力合作，以確保治療效果能夠轉化為永續的患者獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：Castleman氏病治療市場（依治療方法分類）

  • 化療
    • 聯合治療
    • 單藥治療
  • 皮質類固醇
    • 地塞米松
    • 強的松
  • Situximab
  • 托珠單抗

第9章：Castleman氏病治療市場（依治療階段分類）

  • 一線治療
    • 聯合治療
    • 單藥治療
  • 後續治療階段
  • 第二行

第10章：Castleman氏病治療市場：依分銷管道分類

  • 離線
  • 線上

第11章：Castleman氏病治療市場：依最終用戶分類

  • 居家照護環境
    • 自我管理
    • 居家照護服務
  • 醫院
  • 專科診所

第12章：Castleman氏病治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：Castleman氏病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章Castleman氏病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國Castleman氏病治療市場

第16章：中國Castleman氏病治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Cylene Pharmaceuticals, Inc.
  • EUSA Pharma Ltd
  • Every Cure Foundation
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Incyte Corporation
  • Janssen Sciences Ireland UC
  • Novartis AG
  • Pfizer Inc.
  • Recordati SpA
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Senhwa Biosciences, Inc.
  • Summit Therapeutics Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4312A385A340

The Castleman Disease Treatment Market was valued at USD 380.66 million in 2025 and is projected to grow to USD 431.11 million in 2026, with a CAGR of 14.03%, reaching USD 954.52 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 380.66 million
Estimated Year [2026] USD 431.11 million
Forecast Year [2032] USD 954.52 million
CAGR (%) 14.03%

A strategic overview of Castleman disease clinical complexity and the evolving therapeutic and care delivery frameworks shaping treatment decisions

Castleman disease presents a complex clinical and operational challenge that spans immunology, oncology, and rare disease management. Patients experience a spectrum of presentations from unicentric forms amenable to localized intervention to multicentric and systemic variants that demand sustained multidisciplinary care. Diagnostic delays and heterogeneity in clinical presentation intensify unmet needs, while advances in understanding the central role of cytokine signaling have reframed therapeutic priorities across clinical practice.

Over the past decade, therapeutic pathways have moved from empiric use of broad immunosuppression and cytotoxic approaches toward targeted biologic interventions that alter disease trajectory for many patients. Alongside pharmacologic innovation, care delivery models have evolved to encompass home-based regimens, specialty clinic coordination, and integrated patient support mechanisms that address quality of life and adherence. For stakeholders focused on clinical impact and operational feasibility, the treatment landscape requires strategies that reconcile scientific progress with access, reimbursement, and real-world implementation realities.

The most significant shifts reshaping Castleman disease care arising from targeted biologics, biomarker-driven strategies, and novel care delivery models

Recent mechanistic and therapeutic advances have catalyzed transformative shifts across research, clinical practice, and patient support paradigms. A sharper focus on the interleukin-6 pathway and cytokine modulation has redirected research investments to biologics and monoclonal antibodies, while parallel efforts in biomarker discovery aim to stratify patients for more precise interventions and to identify those most likely to derive durable benefit. This scientific pivot is producing a cascade of downstream changes that affect trial design, comparator selection, and regulatory dialogue.

Concurrently, delivery innovation has accelerated. The rise of home administration, telemedicine-enabled follow-up, and integrated specialty clinic networks has reshaped patient touchpoints and adherence frameworks. These changes are accompanied by payer and provider adaptations that emphasize value-based contracting and outcomes-based evidence. Taken together, these shifts require stakeholders to re-evaluate clinical pathways, supply chain resilience, and commercial strategies to align with a landscape that prizes targeted efficacy, patient-centric delivery, and measurable real-world outcomes.

How changes in United States tariff policy in 2025 are influencing supply chains, sourcing strategies, and continuity of access for Castleman disease therapeutics

Tariff adjustments enacted in the United States during 2025 have introduced new considerations for manufacturers, distributors, and care providers involved in treating rare immune-mediated conditions. Even when core biologic agents themselves may be produced under specialized trade terms, ancillary inputs such as active pharmaceutical ingredients, single-use devices, packaging components, and cold-chain logistics are sensitive to cross-border cost shifts. As import duties and logistical surcharges change, stakeholders must reassess sourcing decisions and inventory strategies to preserve continuity of care for vulnerable patient cohorts.

In practice, these supply-side cost pressures can prompt manufacturers to explore nearshoring, alternative supplier qualification, or increased vertical integration to control critical nodes of the value chain. Health systems and specialty pharmacies respond by refining procurement cycles and expanding buffering capabilities to reduce the risk of treatment interruption. From a commercial perspective, negotiations around pricing, contracting, and patient assistance programs will need to incorporate the operational realities of higher landed costs and potential delays. Strategically, organizations that proactively map tariff exposures and build flexible sourcing models will be positioned to maintain access while managing margin implications and preserving treatment adherence for patients.

Deep segmentation insights explaining how treatment types, lines of therapy, distribution channels, and care settings shape clinical and commercial execution

A clear understanding of patient cohorts and therapeutic pathways is essential when interpreting treatment responses and planning commercial approaches. Treatment segmentation distinguishes between chemotherapy approaches and targeted biologics, with chemotherapy further analyzed across combination therapy and monotherapy modalities, and corticosteroid use delineated by agents such as dexamethasone and prednisone. This granularity clarifies where clinical practice favors broad immunosuppression compared to precision targeting, and it informs comparative safety and tolerability discussions that are central to clinician decision-making.

Line-of-therapy segmentation captures how interventions are positioned across first line, second line, and later-line settings, with first-line approaches further differentiated by combination therapy versus monotherapy strategies. Distribution channel distinctions between offline and online pathways reveal differences in patient access, dispensing workflows, and adherence supports. End-user analysis underscores where care is delivered-home care settings, hospitals, or specialty clinics-with further subdivision of home care into self-administration and visiting nurse services to reflect variations in patient independence, training needs, and monitoring intensity. Together, these segmentations enable a multidimensional view of the landscape that supports targeted clinical programs, optimized supply chain planning, and tailored patient services.

How regional differences across the Americas, Europe Middle East & Africa, and Asia-Pacific define access pathways, adoption patterns, and commercial approaches

Regional dynamics exert a powerful influence on clinical adoption, reimbursement strategy, and access pathways. In the Americas, specialized centers and established referral networks accelerate adoption of targeted biologics and support robust clinical trial activity, while payer frameworks and patient assistance programs shape out-of-pocket exposure and formulary positioning. This regional ecosystem tends to favor rapid dissemination of evidence into practice, although disparities in access persist across different care settings and population groups.

The Europe, Middle East & Africa region presents a heterogenous landscape where regulatory processes, reimbursement criteria, and health system structures vary widely. In several Western European markets, centralized expert networks and health technology assessment processes promote evidence-based adoption, whereas other markets within the region experience slower uptake due to resource constraints and distribution barriers. Meanwhile, Asia-Pacific markets combine rapid capacity expansion in biologic manufacturing with cost-sensitive payer environments; variations across countries drive diverse commercial approaches, ranging from local manufacturing partnerships to tiered pricing and digital engagement models aimed at improving access and patient monitoring.

Commercial and development strategies that companies are adopting to differentiate therapies, expand access, and build sustainable evidence generation programs

Leading commercial and development strategies in the Castleman disease space emphasize innovation across the value chain rather than a single point of differentiation. Companies are prioritizing durable clinical benefit through targeted mechanisms of action, expanding indication breadth through investigator-sponsored and registrational studies, and balancing lifecycle management with portfolio diversification to mitigate single-product risk. Strategic partnerships with manufacturing, clinical research organizations, and specialty pharmacies are common tactics to scale complex biologic production and to streamline patient access pathways.

Beyond pipeline and manufacturing considerations, successful organizations invest in patient support programs, real-world evidence generation, and clinician education to accelerate uptake and demonstrate value to payers. Pricing strategies increasingly reflect a blend of upfront list prices supplemented by outcomes-based agreements or risk-sharing models. At the same time, the potential entrance of biosimilar or alternative biologic competitors underscores the importance of differentiation through superior safety profiles, simplified administration, or demonstrable long-term outcomes in real-world settings.

Practical and prioritized recommendations for industry leaders to align clinical innovation, access strategies, and operational resilience for long-term success

Industry leaders should prioritize a set of integrated, actionable moves that align clinical efficacy with access and operational resilience. First, investment in diagnostic precision and biomarker programs will enable more accurate patient selection and stronger payer conversations, reducing uncertainty about comparative effectiveness. Second, diversifying manufacturing and supply partnerships, including regional production capacities and validated alternative suppliers, will mitigate exposure to tariff-driven cost shifts and logistical disruption.

Third, building robust patient support infrastructure that spans home administration training, visiting nurse services, and digital adherence tools will enhance real-world persistence and clinical outcomes. Fourth, engaging payers early to design outcomes-based or value-based contracting arrangements can bridge evidence gaps and unlock coverage while aligning incentives. Finally, companies should adopt an evidence continuum approach that combines randomized data with real-world registries and patient-reported outcomes to support long-term positioning and lifecycle strategy.

A rigorous mixed-methods research approach combining clinical literature, stakeholder interviews, and real-world data triangulation to ensure robust insights

The findings presented here derive from a mixed-methods research approach designed to balance clinical rigor with real-world applicability. The methodology integrates a comprehensive review of peer-reviewed literature and clinical trial registries with qualitative interviews conducted with treating clinicians, specialty pharmacists, and payer representatives to capture practice patterns and reimbursement drivers. Real-world data sources and observational registry evidence were analyzed to validate treatment pathways and to contextualize adherence and safety profiles outside controlled trials.

Data triangulation and cross-validation were employed to ensure robustness, with iterative expert consultations used to interpret ambiguous or inconsistent signals. Key variables such as treatment modality, line of therapy, care setting, and distribution channel were coded consistently to allow comparative analysis across data streams. Throughout the research process, ethical and data governance standards were observed, and findings were synthesized to provide actionable insights that remain grounded in current clinical practice and operational realities.

A concise synthesis of evidence and strategic direction to convert therapeutic innovation into sustained clinical and operational impact for Castleman disease

In conclusion, advances in targeted biologic therapies and evolving care delivery models are reshaping the Castleman disease treatment landscape in ways that create both opportunity and obligation for stakeholders. Scientific progress around cytokine modulation has delivered meaningful improvements for many patients, but structural challenges related to access, supply chain resilience, and variable reimbursement environments remain. Addressing these challenges requires coordinated action across clinical, commercial, and operational domains to ensure that therapeutic gains translate into sustained patient benefit.

Looking ahead, organizations that integrate biomarker-driven patient selection, resilient sourcing strategies, payer-aligned value demonstration, and patient-centric delivery models will be best positioned to convert innovation into real-world impact. A holistic strategy that spans development, market access, and post-approval evidence generation offers the clearest pathway to improving outcomes for patients living with Castleman disease while maintaining commercial viability and operational sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Castleman Disease Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Combination Therapy
    • 8.1.2. Monotherapy
  • 8.2. Corticosteroids
    • 8.2.1. Dexamethasone
    • 8.2.2. Prednisone
  • 8.3. Siltuximab
  • 8.4. Tocilizumab

9. Castleman Disease Treatment Market, by Line Of Therapy

  • 9.1. First Line
    • 9.1.1. Combination Therapy
    • 9.1.2. Monotherapy
  • 9.2. Later Lines
  • 9.3. Second Line

10. Castleman Disease Treatment Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Castleman Disease Treatment Market, by End User

  • 11.1. Home Care Settings
    • 11.1.1. Self Administration
    • 11.1.2. Visiting Nurse Services
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Castleman Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Castleman Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Castleman Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Castleman Disease Treatment Market

16. China Castleman Disease Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Biogen Inc.
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Cylene Pharmaceuticals, Inc.
  • 17.10. EUSA Pharma Ltd
  • 17.11. Every Cure Foundation
  • 17.12. F. Hoffmann-La Roche Ltd
  • 17.13. Genentech, Inc.
  • 17.14. Incyte Corporation
  • 17.15. Janssen Sciences Ireland UC
  • 17.16. Novartis AG
  • 17.17. Pfizer Inc.
  • 17.18. Recordati S.p.A
  • 17.19. Regeneron Pharmaceuticals, Inc.
  • 17.20. Sandoz International GmbH
  • 17.21. Senhwa Biosciences, Inc.
  • 17.22. Summit Therapeutics Inc.
  • 17.23. Swedish Orphan Biovitrum AB
  • 17.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)